Belzutifan
Technology package · Tablets · 40 mg
Technology packageASMF (in preparation)Confidentiality：Highly confidential
- INN / Generic Name
- Belzutifan
- Dosage Form
- Tablets
- Strength
- 40 mg
- Therapy Area
- Anti-cancer
- Indication
- VHL-associated renal cell carcinoma / pancreatic neuroendocrine tumours
- Current Status
- Tech package ready for transfer + local registration pending (within patent term)
- GMP Certification
- GMP-like (in-house facility)
- CEP
- No
- DMF Type
- ASMF (in preparation)
- Stability Data
- 18 months
- BE Required
- Yes
- Registration Pathway
- NP + technology transfer (FSO+)
- MOQ
- 1 project
- Lead Time
- 150 days
- Price Range
- Tech-package licensing US$ 400k-900k
HS Code
— Not a physical good (target / code name / technical service); no customs code applies.
Registrable Markets
BrazilMoroccoAlgeria
Process / Sequence / Exact Price
🔒 Sign a CDA to view process / price / customer
Per our compliance red line, before a CDA is signed we do not disclose sequences, full structures, detailed processes, real customer names or exact prices of pre-launch pipelines. Once you raise an RFQ, the system auto-generates a CDA template; upon admin approval the full data room unlocks.